SELLAS Life Sciences Group Inc Stock
SELLAS Life Sciences Group Inc gained 1.230% today.
Our community identified positive and negative aspects for SELLAS Life Sciences Group Inc stock for the coming years. 1 users see the criterium "Management" as a plus for the SELLAS Life Sciences Group Inc stock. On the other hand our users think that "Innovation" could be a problem in the future.
SELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.
Pros and Cons of SELLAS Life Sciences Group Inc in the next few years
Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Cons
?
M***** P*******
?
S********** s********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of SELLAS Life Sciences Group Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| SELLAS Life Sciences Group Inc | 1.230% | -23.816% | 24.249% | -12.006% | 18.769% | -82.307% | -99.685% |
| Beximco Pharmaceuticals Ltd. GDR | -2.330% | 0.939% | -1.376% | -4.444% | -2.273% | -49.112% | -23.894% |
| Cellectar BioSciences Inc. | 2.820% | -0.685% | -22.043% | 107.143% | 27.193% | -77.344% | - |
| Eledon Pharmaceuticals Inc. | 14.890% | 1.075% | -1.053% | -2.083% | 14.634% | -76.790% | -95.623% |